Assay News and Research

RSS

New methodology helps investigate unfolding of DNA

NYU Langone Medical Center researchers have developed a powerful new method to investigate the discrete steps necessary to turn on individual genes and examine how the process goes wrong in cancer and other diseases. The finding, based on seven years of research and described in the April 9 issue of Molecular Cell, allows scientists to investigate the unfolding of DNA, a process required for gene activation.

9 Apr 2010

Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company has completed enrollment of all subjects for its therapeutic cervical cancer vaccine (VGX-3100) phase I trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18, and is delivered via in vivo electroporation.

8 Apr 2010

Nutritional supplement can increase blood circulation of hematopoietic stem cells

A nutritional supplement could stimulate the production of stem cells integral for repairing the body. Research published in BioMed Central's open access Journal of Translational Medicine suggests that a commercially-available supplement can increase the blood circulation of hematopoietic stem cells, which can give rise to all blood cells, and endothelial progenitor cells, which repair damage to blood vessels.

8 Apr 2010

Illumina launches VeraCode ADME Core Panel

Illumina, Inc. today announced the launch of its VeraCode ADME Core Panel designed to help researchers study genetic predispositions for differential drug response and adverse events. The VeraCode ADME Core Panel offers the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardized by pharmaceutical industry experts in the PharmADME Core List.

From Illumina, Inc. 7 Apr 2010

Accumetrics completes enrollment phase of GRAVITAS clinical trial

Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy to use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced that it has completed the enrollment phase of its landmark clinical trial, GRAVITAS.

7 Apr 2010

Achievements of AFC, Abbott to be highlighted at AFC's 25th Anniversary Gala

Two events occurred in 1985 that proved pivotal in the local and national fight against AIDS: the founding of the AIDS Foundation of Chicago and the development of the first-ever diagnostic test licensed to identify HIV in the blood by Abbott.

6 Apr 2010

Emory University researchers develop experimental clinical test for XMRV

The recently discovered retrovirus, xenotropic murine leukemia virus-related virus (XMRV), has been identified in some prostate cancer patients. In light of conflicting data concerning XMRV, standardized diagnostic testing is important to identify patients in which XMRV is present and to determine whether it plays a role in the incidence of prostate cancer.

6 Apr 2010

AllCells expands office, laboratory production space and staff

AllCells LLC, a leading supplier of primary cell types, today announced it has completed its expansion into 10,000 additional square feet of office and laboratory production space located in Emeryville, California.

5 Apr 2010

Rosetta Genomics' Philadelphia lab commences FNA cell block sample analysis with miRview squamous test

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announced today that starting April 1, 2010 physicians are able to send FNA cell block samples to Rosetta Genomics' CLIA-certified and CAP-accredited laboratory in Philadelphia for analysis using Rosetta's miRview squamous test. FNA is a less invasive method to obtain tumor cells compared with tumor resections or biopsies.

5 Apr 2010

New report questions the kinetics of T cell receptors

T cell receptors are among the most important molecules in the immune system because of their role in recognizing the antigens that signal such threats as viruses and cancer. The receptors must also distinguish these threats from the body's own cells to avoid triggering an unwanted immune system response.

5 Apr 2010

Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusions

3 Apr 2010

Hamamatsu launches FDSS/uCELL imaging plate reader for kinetic cell-based assay development

Hamamatsu has announced the release of the FDSS/uCELL, an affordable new imaging plate reader for kinetic cell-based assay development, including GPCR and ion channel research. The uCELL ("micro cell") offers a cost-effective way for biotechnology companies, research institutes, and clinical research organizations to introduce the highly reliable and advanced Hamamatsu FDSS (Functional Drug Screening System) technology to their daily operations.

2 Apr 2010

Major breakthrough may help develop low toxicity drugs for sleeping sickness

Scientists from the Drug Discovery Unit at the University of Dundee - working together with partners at the University of York and the Structural Genomics Consortium in Toronto - have made a major breakthrough in identifying new treatments for a fatal disease which infects tens of thousands of Africans each year.

1 Apr 2010

FDA accepts for review Abbott's novel diagnostic test for rapid detection of NGAL

A novel diagnostic test to rapidly detect neutrophil gelatinase-associated lipocalin (NGAL), an early biomarker that identifies patients at risk for acute kidney injury (AKI), has been accepted for review by the United States Food and Drug Administration. If approved, this would be the first test available for use in the United States for the detection of NGAL.

1 Apr 2010

FDA clears AdvanDx' 90 minutes protocol for C. albicans PNA FISH and C. albicans/C. glabrata PNA FISH tests

AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its C. albicans PNA FISH® and C. albicans/C. glabrata PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.

31 Mar 2010

NMS Labs launches test to evaluate the efficacy of Milnacipran

NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy, the potential for physicians to establish therapeutic drug monitoring of individual patients, and the assessment of drug diversion of a new pain management drug therapy.

31 Mar 2010

Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced

Novavax, Inc. a clinical-stage vaccine company, released the final results from a Phase II clinical trial evaluating Novavax's trivalent seasonal influenza Virus-like particle (VLP) vaccine candidate in healthy adults. The study enrolled healthy volunteers 18 to 49 years in age who were immunized with a single injection of Novavax's trivalent seasonal influenza VLP vaccine matched to the influenza strains recommended for the 2008-2009 influenza vaccine.

29 Mar 2010

SMARTube technology helps physicians create index to get accurate picture of HIV infection

New data presented at the Center for Disease Control -sponsored 2010 HIV Diagnostics Conference suggests that an assay based on SMARTube™ technology may prove useful in developing a standardized measure for estimating what proportion of those infected with HIV have become recently infected.

29 Mar 2010

Genome sequencing of tumors biopsied from women with invasive breast cancer

Tumors biopsied from women with invasive breast cancer are having their genomes sequenced in an attempt to develop a DNA profile that one day may identify ahead of time the patients who will most likely respond to chemotherapy with an aromatase inhibitor. Aromatase inhibitors are a class of chemotherapeutic agents that block the production of estrogen in postmenopausal women.

27 Mar 2010

Inverness Medical Deutschland to distribute MDI's Detect-Ready MRSA assay in key European markets

Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, and Inverness Medical Deutschland GmbH today announced that they have entered into an exclusive distribution agreement for MDI's Detect-Ready MRSA assay in the key European markets of Germany, Austria and Switzerland.

26 Mar 2010

Assay News and Research

New methodology helps investigate unfolding of DNA

Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine

Nutritional supplement can increase blood circulation of hematopoietic stem cells

Illumina launches VeraCode ADME Core Panel

Accumetrics completes enrollment phase of GRAVITAS clinical trial

Achievements of AFC, Abbott to be highlighted at AFC's 25th Anniversary Gala

Emory University researchers develop experimental clinical test for XMRV

AllCells expands office, laboratory production space and staff

Rosetta Genomics' Philadelphia lab commences FNA cell block sample analysis with miRview squamous test

New report questions the kinetics of T cell receptors

Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusions

Hamamatsu launches FDSS/uCELL imaging plate reader for kinetic cell-based assay development

Major breakthrough may help develop low toxicity drugs for sleeping sickness

FDA accepts for review Abbott's novel diagnostic test for rapid detection of NGAL

FDA clears AdvanDx' 90 minutes protocol for C. albicans PNA FISH and C. albicans/C. glabrata PNA FISH tests

NMS Labs launches test to evaluate the efficacy of Milnacipran

Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced

SMARTube technology helps physicians create index to get accurate picture of HIV infection

Genome sequencing of tumors biopsied from women with invasive breast cancer

Inverness Medical Deutschland to distribute MDI's Detect-Ready MRSA assay in key European markets

eBook: Using iPSCs models for human disease research and drug discovery eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News